Agilis Biotherapeutics' Unattributed - II Round

Agilis Biotherapeutics raised a round of funding on February 24, 2017.

Agilis Biotherapeutics focuses on advancing DNA therapeutics designed to provide long-term efficacy for patients with debilitating, often fatal, rare genetic diseases that affect the central nervous s…

Articles about Agilis Biotherapeutics' Unattributed - II Round: